ACLARION INC Stock Price, News & Analysis

Aclarion (Nasdaq: ACON) participated in the International Society of Pain and Neuroscience Annual Meeting in London on Oct 13, 2025, where a session co‑moderated by Doug Beall, M.D., highlighted the role of MR Spectroscopy and Aclarion’s Nociscan in identifying biomarkers of discogenic low back pain.

Nociscan is described as a SaaS platform that converts MR spectroscopy signals into objective biomarkers to help differentiate painful vs non‑painful lumbar discs and inform personalized treatment decisions. The company emphasized multidisciplinary clinical engagement and insurer approval at a UK clinic for study access.

Aclarion (Nasdaq: ACON) was named a finalist on Oct 7, 2025 for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH in the Rising Star - Clinical Diagnostic Device category.

Nociscan is described as a SaaS platform that transforms MR spectroscopy signals into objective biomarkers to noninvasively distinguish painful from non-painful lumbar discs, supporting more personalized treatment plans. The company cites an estimated 266 million people worldwide living with chronic low back pain and notes it was selected from more than 1,800 submissions.

Aclarion (NASDAQ:ACON) presented at LSI Europe '25, showcasing its Nociscan platform that combines MR spectroscopy with AI to identify chronic low back pain sources. The technology helps physicians differentiate between painful and non-painful lumbar discs, enabling more targeted treatment plans.

The company highlighted its ongoing 300-patient CLARITY randomized clinical trial, which aims to demonstrate improved surgical outcomes beyond the current 54% industry success rate. Interim results are expected in Q2 2026. The company also noted its strengthened balance sheet position to support commercial and clinical initiatives.

Aclarion (NASDAQ:ACON) has announced the enrollment of its first two patients at UHealth – University of Miami Health System in the pivotal CLARITY trial for its Nociscan technology. The study will evaluate Nociscan's effectiveness in improving surgical outcomes for chronic low back pain patients.

The CLARITY trial will enroll 300 patients across multiple US sites, with patients randomized in a 1:1 ratio between surgeons blinded and unblinded to Nociscan results. The trial's primary endpoint is measuring change in back pain at 12 months post-surgery, with interim results expected in Q2 2026.

Nociscan is the first evidence-supported SaaS platform that helps physicians identify painful discs in the lumbar spine through MR Spectroscopy and AI technology, addressing a condition affecting approximately 266 million people globally.

Aclarion (NASDAQ: ACON) has appointed Greg Gould as its new Chief Financial Officer, effective immediately. Gould brings over 30 years of experience and succeeds retiring CFO John Lorbiecki. Throughout his career, Gould has raised more than $450 million in public company financing, led over ten acquisitions, and successfully guided three companies through Nasdaq uplistings.

Most recently serving as CFO at Nanos Health, Gould's extensive experience includes CFO roles at seven publicly-traded companies, including Charlotte's Web and Aytu BioScience. His appointment comes at a crucial time as Aclarion continues to expand the availability of its Nociscan solution, which helps physicians identify painful discs in patients with chronic low back pain.

Aclarion (NASDAQ:ACON) reported significant growth in its Nociscan scan volumes, with a 132% year-over-year increase from Q2 2024 to Q2 2025. The company achieved two consecutive quarters of scan volume growth for the first time, driven by new physician adoption and UK insurance coverage.

Key developments include: the enrollment of the first patient in the pivotal CLARITY trial, which aims to validate Nociscan's effectiveness in improving surgical outcomes for chronic low back pain; publication of a cost-effectiveness analysis showing Nociscan is more effective and less costly than provocative discography; and approval from three major UK private insurers, providing access to over 5.2 million people.

The company reaffirmed its cash runway through Q3 2026, with approximately $15M net cash on hand and no debt. Aclarion expects continued quarter-over-quarter growth throughout 2025 and anticipates internal interim CLARITY trial results by Q2 2026.

Aclarion (NASDAQ: ACON), a healthcare technology company specializing in MRS and AI solutions for back and neck pain treatment, has announced the adjournment of its Annual Meeting of Stockholders. The meeting, originally scheduled for July 7, 2025, will be reconvened on July 21, 2025, at 9:30 a.m. Mountain Time at the company's Broomfield, Colorado office.

The adjournment aims to solicit additional votes for proposals outlined in the company's May 13, 2025 proxy statement. The record date remains May 9, 2025, and previously submitted proxies will remain valid unless properly revoked. Stockholders can modify their votes until 11:59 p.m. Mountain Time on July 20, 2025.

Aclarion (NASDAQ:ACON) has announced the enrollment of its first patient in the CLARITY trial at the Texas Back Institute. The trial aims to evaluate Nociscan's clinical and economic value in spine surgery. Nociscan is a SaaS platform that helps physicians identify sources of chronic low back pain using MR Spectroscopy and AI technology.

The CLARITY trial will enroll 300 patients across multiple US sites, studying 1- or 2-level discogenic low back pain surgical treatments. The randomized study will compare outcomes between surgeons with and without access to Nociscan data. The company expects interim results in Q2 2026, with the primary endpoint measuring changes in back pain at 12 months post-surgery.

Aclarion (NASDAQ: ACON) announced its participation in the State of Spine Surgery Think Tank conference in Cabo San Lucas, June 25-28, 2025. Dr. Kris Radcliff will present the company's NOCISCAN platform, a SaaS solution that uses MR spectroscopy and AI to help identify the source of chronic low back pain.

NOCISCAN is pioneering as the first evidence-supported platform to noninvasively differentiate between painful and nonpainful lumbar spine discs by quantifying chemical biomarkers. The presentation, titled "MR Spectroscopy, Augmented Intelligence, and Low Back Pain - a New Gold Standard," will take place on June 28, 2025, at 10:20 AM.